etavopivat
etavopivat: sourced relationships with 1 company · 12 clinical trials tracked.
etavopivat evidence translation
What we can confirm
12 tracked trials
What it means
What to watch
Prepared research question
How could etavopivat → FMTX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Forma Therapeutics Holdings, Inc. (FMTX) Sickle Cell Disease; Very Low Risk, Low Risk, or Intermediat… | Phase 2 |
Clinical Trial Registry Records (12)showing 10 most recent
A Study to Assess the Effect of Etavopivat on Cardiac Repolarisation in Healthy Participants
Primary endpoint: Part A: Number of treatment-emergent adverse events (AEs)
A Global Phase 3, Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults With Sickle Cell Disease
Primary endpoint: Number of adjudicated Vaso-occlusive crisis (VOC) events with a medical contact
An Open-Label, Fixed-Sequence Study to Evaluate the Effect of Etavopivat on the Single-Dose Pharmacokinetics of Midazolam, Digoxin, Rosuvastatin, Pitavastatin, and Metformin in Healthy Adult Participants
Primary endpoint: Cmax, digoxin, SD: Maximum observed digoxin plasma concentration with and without etavopivat at steady state
A Single-centre, Open-label, Single-group Study Investigating the Pharmacokinetics, Safety and Tolerability After a Single Dose of Oral Etavopivat in Healthy Chinese Participants
Primary endpoint: AUC0-inf,etavopivat: Area under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single dose
A Single-centre, Open-label, Randomised, Single-dose, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of Etavopivat in Healthy Participants
Primary endpoint: AUC0-inf, etavopivat: Area under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single dose
A Multi-centre, Open-label, Parallel-group Study Investigating the Pharmacokinetics, Safety and Tolerability After a Single Dose of Oral Etavopivat in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Participants With Normal Hepatic Function
Primary endpoint: Area under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single dose (AUC0-inf, etavopivat)
A Pilot Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
Primary endpoint: Effect of etavopivat on cerebral blood flow (CBF)
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
Primary endpoint: Change in the highest TAMMV in any of the L/R internal carotid artery [ICA] and L/R middle cerebral artery [MCA], whichever is highest, as measured by TCD
A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Primary endpoint: Single-dose: maximum plasma concentration (Cmax)
A Phase 2 Open-Label Study to Evaluate Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
Primary endpoint: Percentage of Participants With Hematologic Improvement- Erythroid (HI-E) Response for >=8 Weeks Within 24 Weeks of Etavopivat Treatment
Frequently asked questions
Which companies have sourced relationships with etavopivat?
etavopivat has dated SEC/FDA relationship records for Forma Therapeutics Holdings, Inc..
How many clinical trials involve etavopivat?
BioSniper tracks 12 clinical trials involving etavopivat.